Huehls, A. M., Coupet, T. A. & Sentman, C. L. Bispecific T‐cell engagers for cancer immunotherapy. Immunol. Cell Biol. 93, 290–296 (2015).
Rader, C. Bispecific antibodies in cancer immunotherapy. Curr. Opin. Biotechnol. 65, 9–16 (2020).
Weidanz, J. Targeting cancer with bispecific antibodies. Science 371, 996–997 (2021).
de Miguel, M., Umana, P., de Morais, A. L. G., Moreno, V. & Calvo, E. T-cell-engaging therapy for solid tumors. Clin. Cancer Res. 27, 1595–1603 (2021).
Tian, Z., Liu, M., Zhang, Y. & Wang, X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J. Hematol. Oncol. 14, 1–18 (2021).
Smits, N. C. & Sentman, C. L. Bispecific T-cell engagers (BiTEs) as treatment of B-cell lymphoma. J. Clin. Oncol. 34, 1131 (2016).
Krishnamurthy, A. & Jimeno, A. Bispecific antibodies for cancer therapy: a review. Pharmacol. Ther. 185, 122–134 (2018).
Duell, J. et al. Bispecific antibodies in the treatment of hematologic malignancies. Clin. Pharmacol. Ther. 106, 781–791 (2019).
Przepiorka, D. et al. FDA approval: blinatumomab. Clin. Cancer Res. 21, 4035–4039 (2015).
Kantarjian, H. et al. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N. Engl. J. Med. 376, 836–847 (2017).
Labrijn, A. F., Janmaat, M. L., Reichert, J. M. & Parren, P. W. Bispecific antibodies: a mechanistic review of the pipeline. Nat. Rev. Drug Discov. 18, 585–608 (2019).
von Stackelberg, A. et al. Phase I/phase II study of blinatumomab in pediatric patients with relapsed/refractory acute lymphoblastic leukemia. J. Clin. Oncol. 34, 4381–4389 (2016).
Topp, M. S. et al. Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol. 16, 57–66 (2015).
Fadul, C. et al. A phase I study targeting newly diagnosed glioblastoma with anti-CD3× anti-EGFR bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide. Brain Tumor Res. Treat. 10, S193 (2022).
Fiedler, W. et al. Phase I safety and pharmacology study of the EpCAM/CD3-bispecific BiTE antibody MT110 in patients with metastatic colorectal, gastric, or lung cancer. J. Clin. Oncol. 28, 2573–2573 (2010).
Hutchings, M. et al. Glofitamab, a novel, bivalent CD20-targeting T-cell–engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial. J. Clin. Oncol. 39, 1959–1970 (2021).
Heitmann, J. S. et al. Protocol of a prospective, multicentre phase I study to evaluate the safety, tolerability and preliminary efficacy of the bispecific PSMAxCD3 antibody CC-1 in patients with castration-resistant prostate carcinoma. BMJ Open 10, e039639 (2020).
Lum, L. G. et al. Clinical and immune responses to anti-CD3 x anti-EGFR bispecific antibody armed activated T cells (EGFR BATs) in pancreatic cancer patients. Oncoimmunology 9, 1773201 (2020).
Lum, L. G. et al. Phase II clinical trial using anti-CD3× anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) consolidation therapy for HER2 negative (0–2+) metastatic breast cancer. J. Immunother. Cancer 9, e002194 (2021).
Van De Vyver, A. J., Marrer-Berger, E., Wang, K., Lehr, T. & Walz, A.-C. Cytokine release syndrome by T-cell-redirecting therapies: can we predict and modulate patient risk? Clin. Cancer Res. https://doi.org/10.1158/1078-0432.CCR-21-0470 (2021).
Frey, N. V. & Porter, D. L. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematol. Am. Soc. Hematol. Educ. Program 2016, 567–572 (2016).
Stein, A. S. et al. Neurologic adverse events in patients with relapsed/refractory acute lymphoblastic leukemia treated with blinatumomab: management and mitigating factors. Ann. Hematol. 98, 159–167 (2019).
Parker, K. R. et al. Single-cell analyses identify brain mural cells expressing CD19 as potential off-tumor targets for CAR-T immunotherapies. Cell 183, 126–142. e117 (2020).
Goebeler, M.-E. & Bargou, R. C. T cell-engaging therapies—BiTEs and beyond. Nat. Rev. Clin. Oncol. 17, 418–434 (2020).
Gross, G. & Eshhar, Z. Therapeutic potential of T cell chimeric antigen receptors (CARs) in cancer treatment: counteracting off-tumor toxicities for safe CAR T cell therapy. Annu. Rev. Pharmacol. Toxicol. 56, 59–83 (2016).
Kallioniemi, O.-P. et al. ERBB2 amplification in breast cancer analyzed by fluorescence in situ hybridization. Proc. Natl Acad. Sci. USA 89, 5321–5325 (1992).
Morgan, R. A. et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol. Ther. 18, 843–851 (2010).
Morris, E. C., Neelapu, S. S., Giavridis, T. & Sadelain, M. Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy. Nat. Rev. Immunol. 22, 85–96 (2022).
Suurs, F. V., Lub-de Hooge, M. N., de Vries, E. G. & de Groot, D. J. A. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges. Pharmacol. Ther. 201, 103–119 (2019).
Bai, Y., Luo, Q. & Liu, J. Protein self-assembly via supramolecular strategies. Chem. Soc. Rev. 45, 2756–2767 (2016).
Sakamoto, S. & Kudo, K. Supramolecular control of split-GFP reassembly by conjugation of β-cyclodextrin and coumarin units. J. Am. Chem. Soc. 130, 9574–9582 (2008).
Friberg, G. & Reese, D. Blinatumomab (Blincyto): lessons learned from the bispecific T-cell engager (BiTE) in acute lymphocytic leukemia (ALL). Ann. Oncol. 28, 2009–2012 (2017).
Hubsher, G., Haider, M. & Okun, M. Amantadine: the journey from fighting flu to treating Parkinson disease. Neurology 78, 1096–1099 (2012).
Schmid, D. et al. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat. Commun. 8, 1–12 (2017).
McCall, M. J., Diril, H. & Meares, C. F. Simplified method for conjugating macrocyclic bifunctional chelating agents to antibodies via 2-iminothiolane. Bioconjug. Chem. 1, 222–226 (1990).
Ding, Y.-F. et al. Host–guest interactions initiated supramolecular chitosan nanogels for selective intracellular drug delivery. ACS Appl. Mater. Interfaces 11, 28665–28670 (2019).
Estrada, E., Perdomo-López, I. & Torres-Labandeira, J. J. Combination of 2D-, 3D-connectivity and quantum chemical descriptors in QSPR. Complexation of α-and β-cyclodextrin with benzene derivatives. J. Chem. Inf. Comput. Sci. 41, 1561–1568 (2001).
Liu, L. & Guo, Q.-X. Novel prediction for the driving force and guest orientation in the complexation of α-and β-cyclodextrin with benzene derivatives. J. Phys. Chem. B 103, 3461–3467 (1999).
Jiang, W., Kim, B., Rutka, J. T. & Chan, W. C. Nanoparticle-mediated cellular response is size-dependent. Nat. Nanotechnol. 3, 145–150 (2008).
Yuan, H. et al. Multivalent bi-specific nanobioconjugate engager for targeted cancer immunotherapy. Nat. Nanotechnol. 12, 763–769 (2017).
Selvin, P. R. The renaissance of fluorescence resonance energy transfer. Nat. Struct. Biol. 7, 730–734 (2000).
Zhang, B. et al. Site-specific PEGylation of interleukin-2 enhances immunosuppression via the sustained activation of regulatory T cells. Nat. Biomed. Eng. 5, 1288–1305 (2021).
Harris, J. M. & Chess, R. B. Effect of pegylation on pharmaceuticals. Nat. Rev. Drug Discov. 2, 214–221 (2003).
Dreier, T. et al. T cell costimulus-independent and very efficacious inhibition of tumor growth in mice bearing subcutaneous or leukemic human B cell lymphoma xenografts by a CD19-/CD3-bispecific single-chain antibody construct. J. Immunol. 170, 4397–4402 (2003).
Aoki, F. Y. & Sitar, D. S. Clinical pharmacokinetics of amantadine hydrochloride. Clin. Pharmacokinet. 14, 35–51 (1988).
Kim, C., Agasti, S. S., Zhu, Z., Isaacs, L. & Rotello, V. M. Recognition-mediated activation of therapeutic gold nanoparticles inside living cells. Nat. Chem. 2, 962–966 (2010).
Tonga, G. Y. et al. Supramolecular regulation of bioorthogonal catalysis in cells using nanoparticle-embedded transition metal catalysts. Nat. Chem. 7, 597–603 (2015).
Tokumura, T. et al. Enhancement of bioavailability of cinnarizine from its β‐cyclodextrin complex on oral administration with dl‐phenylalanine as a competing agent. J. Pharm. Sci. 75, 391–394 (1986).
Braegelman, A. S. & Webber, M. J. Integrating stimuli-responsive properties in host–guest supramolecular drug delivery systems. Theranostics 9, 3017 (2019).
Castellarin, M. et al. A rational mouse model to detect on-target, off-tumor CAR T cell toxicity. JCI Insight 5, e136012 (2020).
Kim, M. J. & Ahituv, N. in Pharmacogenomics (Innocenti, F. & van Schaik, R. H. N. eds) 279–289 (Springer, 2013).
Arteta, M. Y. et al. Successful reprogramming of cellular protein production through mRNA delivered by functionalized lipid nanoparticles. Proc. Natl Acad. Sci. USA 115, E3351–E3360 (2018).
Zhang, Y., Sun, C., Wang, C., Jankovic, K. E. & Dong, Y. Lipids and lipid derivatives for RNA delivery. Chem. Rev. https://doi.org/10.1021/acs.chemrev.1c00244 (2021).
Min, Y. et al. Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. Nat. Nanotechnol. 12, 877–882 (2017).
Zhou, Q. et al. Mannose-derived carbon dots amplify microwave ablation-induced antitumor immune responses by capturing and transferring ‘danger signals’ to dendritic cells. ACS Nano 15, 2920–2932 (2021).
Norelli, M. et al. Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T cells. Nat. Med. 24, 739–748 (2018).
Chen, F. et al. Measuring IL-6 and sIL-6R in serum from patients treated with tocilizumab and/or siltuximab following CAR T cell therapy. J. Immunol. Methods 434, 1–8 (2016).
Melero, I., Castanon, E., Alvarez, M., Champiat, S. & Marabelle, A. Intratumoural administration and tumour tissue targeting of cancer immunotherapies. Nat. Rev. Clin. Oncol. 18, 558–576 (2021).
Di, S. et al. Combined adjuvant of poly I: C improves antitumor effects of CAR-T cells. Front. Oncol. 9, 241 (2019).
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- PlatoHealth. Biotech and Clinical Trials Intelligence. Access Here.
- Source: https://www.nature.com/articles/s41551-023-01147-6